Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.
Mark H. O'Hara, MD
Advertisement
Articles by Mark H. O'Hara, MD
Advertisement
Latest Updated Articles
Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic AdenocarcinomaPublished: April 4th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
2
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
3
Cognitive Function Improvements Highlighted With Acupuncture Use in Breast Cancer
4
The Battle Between MARIPOSA and FLAURA2 Regimens in NSCLC
5
